Brazil Deploys Single-Shot Vaccine in Pilot War Against Chikungunya

SÃO PAULO, Brazil – February 03, 2026 – In a landmark public health initiative, Brazil has begun deploying a new single-shot chikungunya vaccine in a large-scale pilot program aimed at curbing the devastating impact of the mosquito-borne virus. The campaign, a collaboration between French vaccine maker Valneva, Brazil’s esteemed Instituto Butantan, and the Brazilian Ministry of Health, will see up to 500,000 doses of the IXCHIQ® vaccine administered across ten strategically selected municipalities.

This Pilot Vaccination Strategy (PVS) represents a critical real-world test for a vaccine that has been fast-tracked to combat a disease causing fever and often debilitating joint pain. For Brazil, a country that has reported more chikungunya cases than any other nation, the program is a beacon of hope and a crucial step in its ongoing battle against arboviral diseases.

A Critical Weapon in an Endemic War

The urgency of this vaccination campaign cannot be overstated. Chikungunya has inflicted a heavy toll on Brazil for years. The nation has been the epicenter of the disease in the Americas, recording over one million cases between early 2019 and mid-2024. The crisis has shown no signs of abating, with 2025 alone seeing 247,268 cases and 120 deaths by late December, according to health ministry data. Certain regions, like the state of Mato Grosso, have been declared hotspots, bearing a disproportionate burden of the outbreak.

Even as 2026 begins, the virus remains a persistent threat, with nearly 1,500 suspected cases reported in the first few weeks of the year. The disease, spread by the same Aedes mosquitoes that transmit dengue and Zika, is infamous for causing severe, often chronic, joint pain that can incapacitate individuals for months or even years, leading to significant economic and social disruption.

This pilot program is designed to directly confront this reality. By generating robust data on the vaccine's effectiveness and safety in a large, diverse population actively experiencing transmission, public health officials hope to build a powerful case for wider national use.

The Strategy: Real-World Test for a Novel Vaccine

The PVS is meticulously designed to serve as a post-marketing study. The ten municipalities were chosen based on a combination of epidemiological need and operational capacity, ensuring the data collected will be representative of the challenges faced in endemic regions. The campaign will invite adults between the ages of 18 and 59 to participate, with an ambitious goal of achieving 20% to 40% vaccine coverage within this target demographic.

Valneva, through its partnership with Instituto Butantan, is donating up to 500,000 doses of IXCHIQ® to the Brazilian Ministry of Health to facilitate the program. This donation is a cornerstone of the initiative, enabling rapid deployment without immediate cost barriers to the public health system.

“Contributing to this large-scale pilot vaccination strategy underscores our continued commitment to supporting global preparedness against the growing threat of chikungunya,” said Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, in a statement. He emphasized the importance of the program, noting, “This program is expected to provide additional evidence of the vaccine’s performance and further reinforce its public health value.”

Echoing the collaborative spirit, Esper Kallas M.D., Ph.D., Director of Instituto Butantan, highlighted the rigorous scientific and regulatory groundwork that paved the way for the campaign. "This program stems from a deeply rigorous scientific collaboration between Valneva, Instituto Butantan, and leading arbovirus experts," Kallas stated. "Through continuous engagement with the Ministry of Health, regional health secretaries, and ANVISA, I am confident that we have built a program that is both robust and regulatory-compliant."

A Blueprint for Global Access

Beyond its immediate impact in Brazil, the Valneva-Butantan partnership serves as a potential blueprint for global health equity. The collaboration is built on a January 2021 technology transfer agreement, which aims to eventually empower Instituto Butantan to develop, manufacture, and commercialize the vaccine for the entire Latin American market. This model of localizing production is seen as essential for ensuring sustainable, affordable, and rapid access to critical vaccines in low- and middle-income countries.

The development of IXCHIQ® and its path to deployment have been significantly bolstered by international funding. The Coalition for Epidemic Preparedness Innovations (CEPI) has been a key supporter, awarding Valneva over $40 million in funding since 2019 to advance the vaccine through late-stage trials and prepare it for global licensure and manufacturing. This support was instrumental in achieving WHO prequalification goals, a crucial step for procurement by international agencies like UNICEF.

This multi-pronged approach—combining private sector innovation, public institution expertise, and philanthropic funding—is precisely the kind of strategy the World Health Organization has called for to prevent what it warns could be a major global chikungunya epidemic.

Navigating a New Vaccine Landscape

IXCHIQ® enters the Brazilian market with a strong regulatory tailwind. It made history with its approval by the U.S. FDA in November 2023 and the European Medicines Agency in June 2024. Its approval by Brazil's ANVISA in April 2025 was particularly significant, marking the first time a chikungunya vaccine was authorized for use in an endemic country.

However, it is not the only player in this emerging field. The market is showing signs of competition, with Danish firm Bavarian Nordic's chikungunya vaccine, VIMKUNYA®, recently entering the Brazilian landscape through a distribution agreement with pharmaceutical company Eurofarma. While competition is heating up, IXCHIQ® possesses a key strategic advantage: it is a single-shot vaccine. This simplifies logistics immensely, reducing the resources needed for follow-up appointments and increasing the likelihood of completing the vaccination course—a critical factor in mass immunization campaigns in hard-to-reach areas.

As climate change continues to expand the geographical range of disease-carrying mosquitoes, the threat of chikungunya and other arboviruses is no longer confined to the tropics. The race to develop and deploy effective vaccines is a matter of global health security, and the lessons learned from Brazil’s ambitious pilot program will be watched closely by nations around the world.